MedicaidCoverageMedium impact
24-283m Medication Trend Updates and Formulary Changes - Second Quarter 2024
Health Net·CA · Neurology, Family Medicine, Internal Medicine +1 more·Prior Authorization
We identified it
Jun 20, 2026
Summary
FDA issued safety warnings for antiseizure medications levetiracetam and clobazam due to rare but serious DRESS reactions, and several medications (Trulance, Onglyza, Kombiglyze XR) have been carved out from CalViva Health Medi-Cal coverage to state management. Providers should monitor patients for DRESS symptoms and understand formulary changes affecting Medi-Cal members in Fresno, Kings, and Madera counties.
Action Required
Immediately: Clinical staff should educate patients taking levetiracetam (Keppra, Keppra XR, Spritam) or clobazam (Onfi, Sympazan) about DRESS symptoms including fever, rash, facial swelling, and enlarged lymph nodes. Billing team should verify current formulary status for Trulance, Onglyza, and Kombiglyze XR prescriptions for Medi-Cal patients in Fresno, Kings, and Madera counties as these are now carved out to state management. Contact Medi-Cal Rx at 800-977-2273 for pharmacy benefit questions.